8-K: Illumina Announces Preliminary 2024 Results and Provides 2025 Outlook

Illumina reports preliminary unaudited financial results for Q4 and fiscal year 2024, and provides a preliminary outlook for fiscal year 2025, ahead of its presentation at the J.P. Morgan Healthcare Conference.

Summary

• Illumina announced preliminary unaudited financial results for the fourth quarter and fiscal year 2024.
• The company also provided a preliminary outlook for fiscal year 2025.
• Q4 2024 revenue is approximately $1.10 billion, up 1% from Q4 2023.
• Fiscal year 2024 revenue is approximately $4.33 billion, down 2% from 2023.
• GAAP operating margin for Q4 2024 is approximately 16.7% and 34.2% for fiscal year 2024.
• Non-GAAP operating margin for Q4 2024 is approximately 19.7% and 21.3% for fiscal year 2024.
• GAAP diluted EPS for Q4 2024 is approximately $0.77 $0.79 and $5.65 $5.67 for fiscal year 2024.
• Non-GAAP diluted EPS for Q4 2024 is approximately $0.91 $0.93 and $4.12 $4.14 for fiscal year 2024.
• Cash flow provided by operations is approximately $1.21 billion and free cash flow is approximately $1.07 billion for fiscal year 2024.
• For fiscal year 2025, the company expects constant currency revenue growth in the low single digits.
• Reported revenue for 2025 is expected to be in the range of approximately $4.28 billion to $4.4 billion.
• Non-GAAP operating margin for 2025 is expected to be approximately 23%.
• Non-GAAP diluted EPS growth for 2025 is expected to be approximately 10%.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue growth is modest, the company is projecting improved profitability and EPS growth for the coming year. The preliminary nature of the results and the presence of risks temper the overall sentiment.

Positives

• Q4 2024 revenue increased by 1% compared to Q4 2023, reaching approximately $1.10 billion.
• The company anticipates low single-digit constant currency revenue growth for fiscal year 2025.
• Illumina projects a non-GAAP operating margin of approximately 23% for fiscal year 2025.
• Illumina expects non-GAAP diluted EPS growth of approximately 10% for fiscal year 2025.
• Cash flow provided by operations is approximately $1.21 billion and free cash flow is approximately $1.07 billion for fiscal year 2024.

Negatives

• Fiscal year 2024 revenue decreased by 2% compared to 2023, totaling approximately $4.33 billion.

Risks

• The preliminary unaudited financial results are subject to change upon completion of accounting and annual audit procedures.
• The release contains forward-looking statements that involve risks and uncertainties, including changes in market growth rates, customer order volumes, and the success of competitive products.
• The company's ability to adjust operating expenses, manufacture robust products, and commercialize new offerings are also subject to risks.
• Uncertainty, or adverse economic and business conditions, including as a result of slowing or uncertain economic growth or armed conflict could impact results.
• Legislative, regulatory and economic developments could impact results.

Future Outlook

For fiscal year 2025, Illumina expects constant currency revenue growth in the low single digits, reported revenue in the range of approximately $4.28 billion to $4.4 billion, non-GAAP operating margin of approximately 23%, and non-GAAP diluted EPS growth of approximately 10%.

Industry Context

Illumina's announcement comes amidst ongoing discussions and developments in the genomics and healthcare technology sectors, where companies are striving to innovate and expand their market presence. The company's focus on DNA sequencing and array-based technologies positions it as a key player in the evolving landscape of precision medicine and personalized healthcare.

Comparison to Industry Standards

• It is difficult to compare Illumina's results to industry standards without knowing the specific growth rates and profitability metrics of its direct competitors.
• Companies like Thermo Fisher Scientific, Agilent Technologies, and Pacific Biosciences operate in related markets, but their business models and financial reporting may differ.
• A more detailed analysis would require comparing Illumina's revenue growth, operating margins, and EPS growth to those of its peers, as well as considering factors such as market share, R&D spending, and strategic initiatives.

Stakeholder Impact

• Shareholders will be interested in the company's revenue growth, profitability, and EPS growth.
• Customers will be interested in the company's ability to continue innovating and providing high-quality products and services.
• Employees will be interested in the company's financial performance and its impact on job security and compensation.
• Creditors will be interested in the company's ability to generate cash flow and meet its debt obligations.

Next Steps

• Illumina will report its full fourth quarter and fiscal year 2024 results on February 6, 2025.

Key Dates